Fractyl Health, Inc.
GUTS
NASDAQ·Healthcare·Biotechnology·Mkt cap $110.5M
$0.70
▲ +1.35%
P/E
—
Mkt Cap
$110.5M
52-Wk Range
$0.38–$2.45
52-Week Range
$0.38 - $2.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 25.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary duodenal remodeling technology with durable clinical outcomes
- Novel gene therapy platform targeting pancreatic islet cell dysfunction
- First-mover advantage in metabolic procedure-based diabetes treatment
- Strong intellectual property portfolio protecting innovative mechanisms of action
Bear Case
1 risk
- High volatility (beta 2.3). Larger-than-normal price swings expected.
Growth
Stable outlook
Rising global prevalence of type 2 diabetes and obesity epidemics
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
+4.0% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying GUTS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 10, 2026
Reported EPS of -$0.12 vs -$0.14 consensus (+11.1% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.1%
Revenue trend · last 8Q
—
—
-100%
-100%
-100%
-100%
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$14.0K
$3.0K
$0
$0
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Profit
—
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Jul 1, 2026
vs Industry
How GUTS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related